Zentalis Pharmaceuticals (ZNTL) Operating Expenses (2019 - 2026)

Zentalis Pharmaceuticals has reported Operating Expenses for 8 years, with the latest figure at $37.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 17.03% year-over-year to $37.9 million; the trailing twelve-month figure through Mar 2026 stood at $145.0 million (down 39.29% YoY), and the FY2025 full-year result was $152.8 million, down 40.91% from the prior year.
• Operating Expenses for Q1 2026 stood at $37.9 million, up from $37.4 million in the prior quarter.
• The five-year high for Operating Expenses was $103.9 million in Q2 2023, with the low at $33.7 million in Q3 2025.
• Average Operating Expenses over 5 years is $57.4 million, with a median of $57.9 million recorded in 2022.
• Year-over-year, Operating Expenses soared 63.75% in 2023 and plunged 51.26% in 2025.
• Tracing ZNTL's Operating Expenses over 5 years: stood at $51.8 million in 2022, then surged by 31.24% to $67.9 million in 2023, then increased by 12.94% to $76.7 million in 2024, then sank by 51.26% to $37.4 million in 2025, then rose by 1.24% to $37.9 million in 2026.
• The last three Operating Expenses figures came in at $37.9 million (Q1 2026), $37.4 million (Q4 2025), and $33.7 million (Q3 2025), per Business Quant data.

Peer Comparison